Skip to main content

Brain Health: how early is early enough?


How soon is early enough? The study below supports the need for lifestyle behaviours to improve Brain Health having to start early even before you are middle-aged. In this study of 40- to 54-year-old employees of the Banco Santander in Madrid, Spain who didn’t have any apparent cardiovascular disease were assessed using the 30-year Framingham cardiovascular risk score (FCRS) and other investigations to detect atherosclerosis. A proportion of the 946 of the subjects who had early atherosclerosis underwent metabolic PET imaging of their brain to assess brain metabolism.

Higher 30-year FCRS was associated with global and regional brain hypometabolism, particularly in the parietotemporal region. The carotid artery atherosclerosis burden was associated with this brain hypometabolism, which is an early biomarker of neurodegeneration. These people have poor brain health a reduced brain reserve and are at greater risk of dementia in the future. Importantly, it was hypertension that was the main driver of the high 30-year FCRS, which means we need to prevent and treat hypertension early if we want to maximise our brain health. When I say early it seems as if interventions need to start in your 30s and maybe even earlier.

The big elephant in the room is what drives essential hypertension and is there anything we can do about it? Yes, there is a lot we can do about it. Hypertension is one of the main axes of metabolic syndrome, which also includes abdominal or visceral obesity, diabetes/prediabetes, hypercholesterolaemia/dyslipidaemia and some would argue non-alcoholic fatty liver. Underlying metabolic syndrome is driven by insulin resistance and the downstream effects of insulin resistance.

We now know how to treat insulin resistance with lifestyle interventions and/or medications. The lifestyle intervention includes exercise, a healthy diet low in processed and ultra-processed carbohydrates and biohacking, i.e. using caloric restriction, intermittent fasting or ketogenic diets to flatten your area-under-the-insulin curve. Medications that are used to treat insulin resistance are not actually used to prevent metabolic syndrome but are only prescribed once a component of the disease is diagnosed. What I am saying is sort your lifestyle out and forget about popping pills. 

The message from this study is clear; cardiovascular and brain health is a lifelong challenge. Don’t think you can leave it until you are in your 40s and 50s to tackle it. This is one of the reasons why we have launched our #ThinkBrainHealth global campaign, which is underpinned by an evidence-based international consensus report 'Time matters: a call to prioritize brain health'.


The aim is to help healthcare professionals, policymakers, researchers and the general public to act early to:
  1. promote public understanding that preventing brain disease is possible and that 'what’s good for the heart is good for the brain'
  2. prepare healthcare professionals to manage people with or at risk of neurodegenerative brain disease
  3. prioritize research and build infrastructure to enable prevention, early detection and management of neurodegenerative brain disease.
Cortes-Canteli et al. Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals: The PESA Study. J Am Coll Cardiol. 2021 Feb 23;77(7):888-898.

Background: Atherosclerosis has been linked to cognitive decline in late life; however, the impact of cardiovascular risk factors (CVRFs) and subclinical atherosclerosis on brain metabolism at earlier stages remains unexplored.

Objectives: This study sought to determine the association between brain metabolism, subclinical atherosclerosis, and CVRFs in middle-aged asymptomatic individuals.

Methods: This study included 547 asymptomatic middle-aged participants (50 ± 4 years, 82% men) from the PESA (Progression of Early Subclinical Atherosclerosis) study with evidence of subclinical atherosclerosis. Participants underwent 18F-fluorodeoxyglucose (FDG)-positron emission tomography. Global brain FDG uptake and voxel-wise analyses were used to evaluate the associations of cerebral metabolism with CVRFs and atherosclerotic plaque burden in carotids and femorals assessed by 3-dimensional vascular ultrasound.

Results: Global FDG uptake showed an inverse correlation with 30-year Framingham Risk Score (FRS) (β = -0.15, p < 0.001). This association was mainly driven by the presence of hypertension (d = 0.36, p < 0.001). Carotid plaque burden was inversely associated with global brain FDG uptake (β = -0.16, p < 0.001), even after adjusting for 30-year FRS. Voxel-wise approaches revealed that the brain areas most strongly affected by hypometabolism in association with 30-year FRS, hypertension, and carotid plaque burden were parietotemporal regions (angular, supramarginal, and inferior/middle temporal gyri) and the cingulate gyrus.

Conclusions: In asymptomatic middle-aged individuals, cardiovascular risk is associated with brain hypometabolism, with hypertension being the modifiable CVRF showing the strongest association. Subclinical carotid plaque burden is also linked to reduced brain metabolism independently of CVRFs. Cerebral areas showing hypometabolism include those known to be affected in dementia. These data reinforce the need to control CVRFs early in life in order to potentially reduce the brain's midlife vulnerability to future cognitive dysfunction.

CoI: multiple

Twitter: @gavinGiovannoni                         Medium: @gavin_24211

Labels:

Comments

Post a Comment

Popular posts from this blog

Are you ready for an EBV vaccine to prevent MS?

"Professor Giovannoni, you tell me that my daughter has a 1 in 40 chance of developing multiple sclerosis and that MS has reached epidemic proportions in parts of the world? Is there anything I can do to reduce her chances of getting MS? Is there anything we can do to stop other people from getting MS?" Although multiple sclerosis (MS) is a complex disease due to the interaction of genetic and environmental factors data on the occurrence of MS at the population level (epidemiology) supports the Epstein Barr Virus (EBV) as being necessary, but not sufficient, for someone to develop MS. In other words, EBV is probably the cause of MS. Of all the putative causative agents that have been proposed to be associated with MS, EBV is the only one where the risk of getting MS if you are EBV negative is close to zero or zero if you limit the analyses to those studies which use a technique called immunofluorescence microscopy as the gold-standard assay to detect anti-EBV antibodies. EBV ...
7 comments
Read more

Smoking: a major preventable MS risk factor

I have been complaining about my low productivity levels since I have gotten back to work after my accident. However, last night with a single one hour webinar we have managed to set-up a new international collaboration to study and address the social determinants of health (SDoH) and their impact on MS. Our focus is going to be on which SDoH can we modify and hence improve the outcome for people with MS (pwMS)? Smoking is one such modifiable factor and needs to be addressed at a (1) population level with policy and legislation, (2) at a local or community level, (3) with the family and (4) at an individual level target the people with MS (pwMS). We know that pwMS who smoke have a worse outcome than people who don’t smoke. The effect of smoking is equivalent to negating the treatment effect of being on an injectable therapy such as interferon beta. Put simply smokers with MS start using a walking stick (EDSS = 6.0) about 6 years earlier than pwMS who don’t smoke. Getting pwMS to stop s...
7 comments
Read more

Corpulence and poverty

Since stating my intention to join the  #BackTo21  campaign to get my BMI back to what it was when I was 21 years of age, I have had several emails and direct messages on social media questioning the wisdom of my intention.  Photo by NeONBRAND on Unsplash It is clear that despite BMI being a relatively poor metric of health there is overwhelming evidence that at a population level it predicts poor health outcomes. Importantly there is new data that indicates the target BMI for the prevention of type 2 diabetes and the metabolic syndrome depends on your ethnicity. For people of South Asian origin, there is a call to reset the BMI cutoff to 23.9, which for most people is within the normal range. At the same time, there is a call to classify obesity as an important social determinant of health. Arnaud Chiolero argues below for using BMI as a socioeconomic indicator. Do you agree? Isn’t it quite amazing that in a previous era corpulence was a sign of affluence, whereas in th...
4 comments
Read more